Kutatási jelek – Signal Engine

• Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma — Mantle cell lymphoma
• Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment — Chronic lymphocytic leukemia
• Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma — Mantle cell lymphoma
• Uveal Melanoma Treatment: An Update. — Uveal melanoma
• Social determinants in the delay of starting colorectal cancer treatment — Colorectal cancer
• Historic Real-World Outcomes and Future Benchmarks for Patients with Diffuse Large B-Cell Lymphoma Receiving First- and Second-Line Therapy in Austria – a Large Single-Center Experience — Diffuse large B-cell lymphoma
• Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma — Diffuse large B-cell lymphoma
• Annual Clinical Updates in Hematological Malignancies: Update on the Management of Diffuse Large B‑Cell Lymphoma — Diffuse large B-cell lymphoma
• Clinical Outcomes of Breast‑Involved Diffuse Large B‑Cell Lymphoma Treated with R‑CHOP: A Real‑World Study with Insights into CNS Prophylaxis — Breast cancer
• Hyperpolarized (13)C Pyruvate MRI/MRS for Characterizing Splenic Metabolism in Advanced Diffuse Large B-Cell Lymphoma: A Pilot Study — Diffuse large B-cell lymphoma
• Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B‑cell lymphoma — Diffuse large B-cell lymphoma
• Longitudinal NSCLC Treatment Progression via Multimodal Generative Models — NSCLC
• Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma — Diffuse large B-cell lymphoma
• Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy. — Renal cell carcinoma
• Spatial Profiling and Prognostic Role of Tumor-Infiltrating CD8+ T and CD20+ B Cells in Metastatic Clear Cell Renal Cell Carcinoma Treated with Sequential Tyrosine Kinase Inhibitors and Nivolumab — Hepatocellular carcinoma
• Melatonin Inhibits Metastasis of Sunitinib‑Resistant Renal Cell Carcinoma Cells Via the GRP78/p38/CTSD Expression — Renal cell carcinoma
• Prognostic Value of the Lung Immune Prognostic Index in Metastatic Renal Cell Carcinoma Treated With Second‑Line Immunotherapy — Renal cell carcinoma
• Effectiveness of Acupuncture and Moxibustion for Non‑Small Cell Lung Cancer Patients Undergoing Standard Treatment: A Systematic Review and Meta‑Analysis — NSCLC
• Five‑Year Unified Risk Prediction Model for Gastric and Esophageal Cancer Based on Nationwide Health Check‑Up Data in Japan: J‑GESS Score — Gastric cancer
• Neighborhood Factors and Treatment Outcomes in Pediatric Acute Lymphoblastic Leukemia: A REDIAL Consortium Report. — Acute lymphoblastic leukemia